Skip to main content

Advertisement

Table 3 Chemotherapy studies in advanced biliary tract cancer

From: A phase II study of capecitabine and oxaliplatin combination chemotherapy in patients with inoperable adenocarcinoma of the gall bladder or biliary tract

Author (year) Drug Number of patients Response rate (%)
Taal (1993) [32] MMC 30 10
Patt (1996) [33] 5FU 32 34
Interferon alfa-2b
Patt (2001) [34] Cisplatin Interferon alpha-2b 41 21
Doxorubicin
5 FU
Penz (2001) [35] Gemcitabine 32 22
Murad (2003) [36] Gemcitabine 26 31
5FU   
Kornek (2001) [37] MMC/Capecitabine vs 51 31
MMC/gemcitabine 20
Ueno (2004) [38] S1 19 21
Alberts (2005) [39] Gem 42 9.5
5FU
Leucovorin
Furuse (2006) [40] Uracil-tegafur 24 12.5
Doxorubicin
Kim (2006) [41] Gemcitabine 29 34.5
Cisplatin
Okusaka (2006) [42] Gemcitabine 40 17.5
Park (2006) [43] Gemcitabine 27 33.3
Cisplatin
Hong (2007) [44] Capecitabine 32 40.6
Cisplatin
Manzione (2007) [23] Gemcitabine 34 41
Oxaliplatin
Furuse (2008) [45] S1 40 35
Kim (2008) [46] S1 51 30
Cisplatin
Oh (2008) [27] S1 15 6.7
Oxaliplatin
Furuse (2009) [47] Uracil-tegafur 61 6.6
Doxorubicin
Kim (2009) [25] Gemcitabine 40 15
Oxaliplatin
Sasaki (2009) [48] S1 28 34.3
Gemcitabine
Gruenberger (2010) [30] Cetuximab 30 63
  Gemcitabine
  Oxaliplatin
Gunnlaugsson (2010) [22] Capecitabine 39 21
  Oxaliplatin
Kanai (2010) [49] S1 25 30.4
Gemcitabine
Karachaliou (2010) [24] Irinotecan 28 17.9
Oxaliplatin
Chung (2011) [50] Irinotecan 39 20.5
Gemcitabine